IDXG
Interpace Biosciences, Inc.
$1.63
+0.02 (+1.24%)
At close · Jul 2
Market Cap
$45.15M
Shares
27,700,904
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.63
Open$1.61
Day$1.61–1.63
52W$0.75–2.40
Avg vol 30d4K
Short int785 · 0.0% float · 1.0d
Short vol47%
Last earningsMay 14, 2026
DataJul 2024–Jul 2026
Filing10-Q · May 12
Equibles Rating
blended score · not investment advice
Overall
Buy
Technical · trend & momentum
Buy
◦
50 / 200-day cross
no cross
+
Price vs 200-day avg
+10% above
−
Price vs 50-day avg
−10% below
◦
RSI (14)
43 · neutral
+
MACD trend
positive
◦
52-week position
53% · mid-range
Sentiment · smart money
Bearish
◦
Trend (MA cross)
50d $2 › 200d $1 — 50d above 200d
−
Institutional flow
-77% holders QoQ · +2 funds added
◦
Insider flow
No net insider activity over 90 days
−
Short interest
0.00% of float · ▲ +7750.0% MoM · 1.0 days cover
◦
Volume signal
Volume near normal
◦
Institution breadth
3 holders — near 1-yr low, contrarian setup
Fundamentals
Excellent
−
Revenue growth
−31% Y/Y
+
Gross margin
425%, expanding
+
EPS growth
+123% Y/Y
+
Free cash flow
$5.5M
+
Valuation
P/E 1.9 · below peers
+
Balance sheet
net cash $2.5M
Blended from price, positioning & fundamentals · daily-close · not investment advice.
Up next
Next earnings call
Aug 16, 2026
Est · unconfirmed
· in 6 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 12, 2026
Guidance & track record
Latest guidance
· from the 8-K filed May 14, 2026
Thyroid revenue growth
· 2026
up to 16%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
no cross
Neutral
Price vs 200-day avg
+10% above
Bullish
Price vs 50-day avg
−10% below
Bearish
RSI (14)
43 · neutral
Neutral
MACD trend
positive
Bullish
52-week position
53% · mid-range
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $2 › 200d $1 — 50d above 200d
Institutional flow
Distributing
-77% holders QoQ · +2 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.00% of float · ▲ +7750.0% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr low
3 holders — near 1-yr low, contrarian setup
Price context
position in its 52-week range
52-wk low $1
Now $2 · 53%
52-wk high $2
vs 200-day avg +10%
vs 50-day avg -10%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from its earnings releases and calls| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $1.6M | Q1 2026 | — |
|
|
|||
| Adjusted EBITDA margin non-GAAP | 17% | Q1 2026 | — |
| Average thyroid revenue per test year-over-year increase | 3% | Q1 2026 | — |
| Average volume per account year-over-year increase | 9% | Q1 2026 | — |
| Cash collections | $8.7M | Q1 2026 | — |
| Days sales outstanding (DSO) year-over-year improvement | 6% | Q1 2026 | — |
| Number of accounts year-over-year increase | 5% | Q1 2026 | — |
| Thyroid revenue year-over-year increase | 12% | Q1 2026 | — |
| Thyroid volume year-over-year increase | 10% | Q1 2026 | — |
| Turnaround time year-over-year improvement | 21% | Q1 2026 | — |
| Full Year cash collections | $41.7M | Full Year 2025 | — |
| Full Year Thyroid revenue year-over-year increase | 21% | Full Year 2025 | — |
| Full Year Thyroid volume year-over-year increase | 13% | Full Year 2025 | — |
| Q4 cash collections | $9.6M | Q4 2025 | — |
| Q4 Thyroid revenue year-over-year increase | 14% | Q4 2025 | — |
| Q4 Thyroid volume year-over-year increase | 11% | Q4 2025 | — |
Figures exactly as the company stated them · click a metric with a to chart its history · period links open the stating document · "call" marks figures stated on the earnings call · YoY needs the prior-year figure on file
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IDXG
this stock
Interpace Biosciences, Inc.
|
$45.15M | +32.5% | -30.7% | 1.9 | 0.0% |
|
TMO
Thermo Fisher Scientific Inc.
|
$194.52B | -9.6% | +0.4% | 28.8 | 1.2% |
|
DHR
Danaher Corp /De/
|
$140.09B | -13.4% | +8.5% | 38.2 | 1.6% |
|
IDXX
Idexx Laboratories Inc /De
|
$44.00B | -17.5% | +10.4% | 41.0 | 2.7% |
|
NTRA
Natera, Inc.
|
$40.00B | +21.9% | -2.8% | — | 3.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Reducing
Holders
3
- % held
- 0.0%
- Net QoQ
- -258.9K sh
- Top holder
- HRT FINANCIAL LP
Held
Float
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IDXG | -0.6% | -7.4% | +48.2% | +0.0% | +32.5% |
| SPY | +1.4% | -1.3% | +8.0% | -0.3% | +9.2% |
| vs SPY | -2.0% | -6.1% | +40.2% | +0.3% | +23.3% |